NCT03336866View on ClinicalTrials.gov

Study of Antibody for Methamphetamine Outpatient Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

May 3, 2018

Primary Completion Date

November 23, 2020

Study Completion Date

March 9, 2021

Conditions
Methamphetamine-dependenceMethamphetamine Abuse
Interventions
DRUG

Placebo

Normal saline

DRUG

IXT-m200

IXT-m200 is an anti-methamphetamine monoclonal antibody

Trial Locations (2)

84124

PRA Health Sciences, Salt Lake City

92801

Anaheim Clinical Trials, Anaheim

Sponsors
All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

InterveXion Therapeutics, LLC

INDUSTRY